Clinical Trials Logo

Clinical Trial Summary

Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complication can be reduced by following the Z-track technique; however, fluid leaks still occur causing significant morbidity. 2-Octyl cyanoacrylate (2-OCA, Dermabond manufactured by Ethicon Inc) skin adhesive has been used for years for skin closure for wounds from surgical incisions including punctures from minimally invasive surgery and simple trauma lacerations.


Clinical Trial Description

Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complication can be reduced by following the Z-track technique; however, fluid leaks still occur causing significant morbidity. 2-Octyl cyanoacrylate (2-OCA, Dermabond manufactured by Ethicon Inc) skin adhesive has been used for years for skin closure for wounds from surgical incisions including punctures from minimally invasive surgery and simple trauma lacerations. It has also been used for treatment of ascites fluid leaks following paracentesis with success in case reports. While the initial FDA approval included a contraindication for use on mucosal surfaces, some evidence in literature suggests that use on mucosal surfaces might warrant further investigation. For example, 2-OCA has been used for repair of a lacerated tongue of a pediatric patient and for closure of congenital cleft lips ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05278013
Study type Interventional
Source Methodist Health System
Contact
Status Enrolling by invitation
Phase N/A
Start date January 13, 2022
Completion date January 13, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Recruiting NCT00239096 - Prevention of Decompensation in Liver Cirrhosis Phase 4
Active, not recruiting NCT03973866 - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) N/A
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Terminated NCT01455246 - Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Completed NCT01578226 - Procalcitonin in Cirrhotic Patients at High Risk for Sepsis N/A
Terminated NCT00548366 - Sodium Restriction in the Management of Cirrhotic Ascites Phase 4
Recruiting NCT05025878 - 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Completed NCT03327688 - Point-of-care Ultrasound in Finland N/A
Not yet recruiting NCT04550091 - Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
Completed NCT01769040 - Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis Phase 4
Not yet recruiting NCT01716611 - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Phase 4
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Recruiting NCT05511766 - Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Phase 2/Phase 3
Completed NCT05013502 - Empagliflozin in Diuretic Refractory Ascites Phase 1
Not yet recruiting NCT06436807 - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Completed NCT03263598 - Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
Completed NCT00907673 - The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure N/A
Suspended NCT00511394 - Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis N/A
Terminated NCT00796861 - Trial of Sunitinib for Refractory Malignant Ascites Phase 2